PMID- 15475075
OWN - NLM
STAT- MEDLINE
DCOM- 20041202
LR  - 20151119
IS  - 0145-2126 (Print)
IS  - 0145-2126 (Linking)
VI  - 28
IP  - 12
DP  - 2004 Dec
TI  - Establishment and characterization of a new human erythroleukemic cell line, 
      ERY-1.
PG  - 1329-39
AB  - The growth factor-independent erythroleukemic cell line ERY-1 was established 
      from the peripheral blood of a 87-year-old woman with chronic myeloid leukemia 
      (CML) in the acute phase. Immunophenotyping showed that fresh leukemic cells were 
      positive for CD13, CD33, CD36 and CD235a (glycophorin A), a phenotype compatible 
      with that of erythroblastic cells. Cytogenetic and fluorescence in situ 
      hybridization (FISH) analysis demonstrated classical t(9;22)(q34;q11) chromosomic 
      translocation associated with a duplication of the BCR-ABL fusion gene. Other 
      cytogenetic abnormalities were detected in all analyzed mitosis, the most 
      frequent being a trisomy of chromosome 8. The established ERY-1 cell line retains 
      these immunophenotypic and cytogenetic features, and light and electron 
      microscopy confirmed the relatively mature erythroblastic phenotype of the cells. 
      In addition, ERY-1 cell line expressed beta-globin mRNA and a non-phosphorylable 
      form of the erythropoietin receptor, even in presence of erythropoietin. Of note, 
      the proliferation of ERY-1 cells was inhibited by TGFbeta1 or STI-571 (Gleevec), 
      without significant induction of further differentiation. In conclusion, ERY-1 is 
      a new growth factor-independent human erythroleukemic cell line with a relatively 
      mature phenotype that may be useful to study the molecular events involved in 
      erythroblastic differentiation.
FAU - Ribadeau Dumas, Antoine
AU  - Ribadeau Dumas A
AD  - Unite CNRS UMR 8147, Faculte de Pharmacie et Hopital Necker 4, Avenue de 
      l'Observatoire 75006, Paris, France.
FAU - Hamouda, Nadine Ben
AU  - Hamouda NB
FAU - Leriche, Laurence
AU  - Leriche L
FAU - Piffaut, Marie-Claude
AU  - Piffaut MC
FAU - Bonnemye, Patrick
AU  - Bonnemye P
FAU - Kuen, Rene Lai
AU  - Kuen RL
FAU - Tricottet, Viviane
AU  - Tricottet V
FAU - Merle-Beral, Helene
AU  - Merle-Beral H
FAU - N'Guyen Khac, Florence
AU  - N'Guyen Khac F
FAU - Arock, Michel
AU  - Arock M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - 0 (Antigens, CD)
RN  - 0 (Benzamides)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 0 (Receptors, Erythropoietin)
RN  - 0 (TGFB1 protein, human)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - 9004-22-2 (Globins)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, CD/analysis
MH  - Benzamides
MH  - *Cell Line, Tumor
MH  - Chromosomes, Human, Pair 8
MH  - Female
MH  - Fusion Proteins, bcr-abl/genetics
MH  - Gene Duplication
MH  - Globins/genetics
MH  - Humans
MH  - Imatinib Mesylate
MH  - Immunophenotyping
MH  - Leukemia, Erythroblastic, Acute/*pathology
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
MH  - Phenotype
MH  - Piperazines/pharmacology
MH  - Pyrimidines/pharmacology
MH  - Receptors, Erythropoietin/metabolism
MH  - Transforming Growth Factor beta/pharmacology
MH  - Transforming Growth Factor beta1
MH  - Translocation, Genetic
MH  - Trisomy
EDAT- 2004/10/12 09:00
MHDA- 2004/12/16 09:00
CRDT- 2004/10/12 09:00
PHST- 2003/12/12 00:00 [received]
PHST- 2004/04/28 00:00 [accepted]
PHST- 2004/10/12 09:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/10/12 09:00 [entrez]
AID - S0145212604001857 [pii]
AID - 10.1016/j.leukres.2004.04.013 [doi]
PST - ppublish
SO  - Leuk Res. 2004 Dec;28(12):1329-39. doi: 10.1016/j.leukres.2004.04.013.